Pulmonary pharmacology and therapeutics

Pulmonary pharmacology and therapeutics

Childhood-onset severe hypereosinophilic asthma: efficacy of benralizumab
Jocelyne Just, Melisande Bourgoin, Flore Amat, Nathalie Cottel, Nathalie Lambert, Stephanie Wanin

ERJ Open Research Oct 2020, 6 (4) 00339-2020; DOI: 10.1183/23120541.00339-2020
Adherence to disease-specific drug treatment among patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension
Barbro Kjellström, Anna Sandqvist, Clara Hjalmarsson, Magnus Nisell, Per Näsman, Bodil Ivarsson

ERJ Open Research Oct 2020, 6 (4) 00299-2020; DOI: 10.1183/23120541.00299-2020
An innovative phase II trial to establish proof of efficacy and optimal dose of a new inhaled epithelial sodium channel inhibitor BI 1265162 in adults and adolescents with cystic fibrosis: BALANCE-CF^TM 1
Christopher H. Goss, Raksha Jain, Wolfgang Seibold, Anne-Caroline Picard, Ming-Chi Hsu, Abhya Gupta, Isabelle Fajac

ERJ Open Research Oct 2020, 6 (4) 00395-2020; DOI: 10.1183/23120541.00395-2020
Preclinical evaluation of the epithelial sodium channel inhibitor BI 1265162 for treatment of cystic fibrosis
Peter Nickolaus, Birgit Jung, Juan Sabater, Samuel Constant, Abhya Gupta

ERJ Open Research Oct 2020, 6 (4) 00429-2020; DOI: 10.1183/23120541.00429-2020
CXCL-8-dependent and -independent neutrophil activation in COPD: experiences from a pilot study of the CXCR2 antagonist danirixin
Holly R. Keir, Hollian Richardson, Christina Fillmore, Amelia Shoemark, Aili L. Lazaar, Bruce E. Miller, Ruth Tal-Singer, James D. Chalmers, Divya Mohan

ERJ Open Research Oct 2020, 6 (4) 00583-2020; DOI: 10.1183/23120541.00583-2020
Azithromycin for sarcoidosis cough: an open-label exploratory clinical trial
Simon D. Fraser, Susannah Thackray-Nocera, Marica Shepherd, Rachel Flockton, Caroline Wright, Wayne Sheedy, Kayleigh Brindle, Alyn H. Morice, Paul M. Kaye, Michael G. Crooks, Simon P. Hart

ERJ Open Research Oct 2020, 6 (4) 00534-2020; DOI: 10.1183/23120541.00534-2020
Steroid-sparing effects of benralizumab in patients with eosinophilic granulomatosis with polyangiitis
Alexandra M. Nanzer, Jaideep Dhariwal, Joanne Kavanagh, Andrew Hearn, Mariana Fernandes, Louise Thomson, Cris Roxas, Linda Green, Grainne D'Ancona, Sangita Agarwal, Brian D. Kent, David J. Jackson

ERJ Open Research Oct 2020, 6 (4) 00451-2020; DOI: 10.1183/23120541.00451-2020
Clinical experience with antifibrotics in fibrotic hypersensitivity pneumonitis: a 3-year real-life observational study
Vasilios Tzilas, Argyris Tzouvelekis, Evangelos Bouros, Theodoros Karampitsakos, Maria Ntassiou, Eleni Avdoula, Athena Trachalaki, Katerina Antoniou, Ganesh Raghu, Demosthenes Bouros

ERJ Open Research Oct 2020, 6 (4) 00152-2020; DOI: 10.1183/23120541.00152-2020
Design and rationale of two phase 3 randomised controlled trials (COUGH-1 and COUGH-2) of gefapixant, a P2X3 receptor antagonist, in refractory or unexplained chronic cough
David R. Muccino, Alyn H. Morice, Surinder S. Birring, Peter V. Dicpinigaitis, Ian D. Pavord, Christopher Assaid, Huub Jan Kleijn, Azher Hussain, Carmen La Rosa, Lorcan McGarvey, Jaclyn A. Smith

ERJ Open Research Oct 2020, 6 (4) 00284-2020; DOI: 10.1183/23120541.00284-2020
(Oral) enoximone in asthma
Jan Beute

ERJ Open Research Oct 2020, 6 (4) 00319-2020; DOI: 10.1183/23120541.00319-2020

Main menu

User menu

Search

Pulmonary pharmacology and therapeutics

Pages

Contact us